Idarubicin hydrochloride
  • Approved Drug Name
    Idarubicin hydrochloride
  • CAS NO.
  • Quality Standard
    USP, JP
  • Packaging
    10G/Bag, 20G/Bag
  • Storage Condition
    Shading,Sealing,Store at room temperature
  • Certification
    Ongoing registration

Idarubicin hydrochloride(casno.57852-57-0): Mechanism of Action:
Idarubicin hydrochloride(casno.57852-57-0) is a DNA-intercalating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and interacts with the enzyme topoisomerase II. The absence of a methoxy group at position 4 of the anthracycline structure gives the compound a high lipophilicity which results in an increased rate of cellular uptake compared with other anthracyclines.
Idarubicin hydrochloride(casno.57852-57-0) is the hydrochloride salt preparation of Idarubicin (IDA) (sc-204774), an anthracycline and an analog of daunorubicin (sc-218089). IDA is rapidly metabolized to its 13-dihydroderivative (Idarubicinol) which is more stable than the parent form. This compound has been reported to trigger apoptotic cell death via enhancement of Fas and caspase-3/caspase-7 expression. In experiments, where cells were exposed to IDA, reactive oxygen species (ROS) were produced which induced DNA strand breaks and prevented DNA polymerase reaction. Idarubicin hydrochloride(casno.57852-57-0) is an inhibitor of Topo II α. Idarubicin hydrochloride(casno.57852-57-0) is also a substrate of CYP2D6 and CYP2C9.
Idarubicin hydrochloride(casno.57852-57-0) Synonyms: (7S,9S)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione Hydrochloride; 4-DMD HCl; 4-Demethoxydaunorubicin Hydrochloride; Idamycin; NSC 256439; Zavedos;
Idarubicin hydrochloride(casno.57852-57-0) Appearance: Orange to Red-Orange Solid
Idarubicin hydrochloride(casno.57852-57-0) Melting Point: >156°C (dec.)
Idarubicin hydrochloride(casno.57852-57-0) Mol. Weight: 533.95
Idarubicin hydrochloride(casno.57852-57-0) Category: Drug Analogues, Pharmaceuticals, Intermediates & Fine Chemicals
Idarubicin hydrochloride(casno.57852-57-0) Warnings:
1. Idarubicin hydrochloride(casno.57852-57-0) for injection should be given slowly into a freely flowing intravenous infusion. It must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration.
2. As is the case with other anthracyclines the use of Idarubicin hydrochloride(casno.57852-57-0) for injection can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have preexisting cardiac disease.
3. As is usual with antileukemic agents, severe myelosuppression occurs when Idarubicin hydrochloride(casno.57852-57-0) for injection is used at effective therapeutic doses.
4. It is recommended that Idarubicin hydrochloride(casno.57852-57-0) for injection be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.
5. Dosage should be reduced in patients with impaired hepatic or renal function. (See DOSAGE AND ADMINISTRATION.)
Idarubicin hydrochloride(casno.57852-57-0) for injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American- British (FAB) classifications M1 through M7. 
Idarubicin hydrochloride(casno.57852-57-0) for injection is intended for administration under the supervision of a physician who is experienced in leukemia chemotherapy. 
Idarubicin hydrochloride(casno.57852-57-0) for injection is a potent bone marrow suppressant. Idarubicin hydrochloride(casno.57852-57-0) for injection should not be given to patients with pre-existing bone marrow suppression induced by previous drug therapy or radiotherapy unless the benefit warrants the risk. 
Pre-existing heart disease and previous therapy with anthracyclines at high cumulative doses or other potentially cardiotoxic agents are co-factors for increased risk of idarubicin-induced cardiac toxicity and the benefit to risk ratio of idarubicin therapy in such patients should be weighed before starting treatment with Idarubicin hydrochloride(casno.57852-57-0) for injection.
Idarubicin hydrochloride Quality
Idarubicin hydrochloride Manufacturers
Idarubicin hydrochloride Suppliers
Idarubicin hydrochloride FDA
Idarubicin hydrochloride USP.EP
Idarubicin hydrochloride GMP
Idarubicin hydrochloride price
Idarubicin hydrochloride samples
More About Idarubicin hydrochloride(casno.57852-57-0):
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Idarubicin hydrochloride(casno.57852-57-0) - A lay language summary of important information about this drug that may include the following:
Warnings about Idarubicin hydrochloride(casno.57852-57-0),
What does Idarubicin hydrochloride(casno.57852-57-0) used for and how it is used,
What you should tell your doctor before using Idarubicin hydrochloride(casno.57852-57-0),
What you should know about Idarubicin hydrochloride(casno.57852-57-0) before using it,
Other drugs that may interact with Idarubicin hydrochloride(casno.57852-57-0), and possible side effects.

bet007足球比分手机版 长春微乐麻将官网下载 2017独胆公式 狗粮真的赚钱吗 美女麻将游戏小游戏 河南十一选五 北京麻将有没有作弊器有 微信公众号如运营何赚钱 广西快乐10分开奖视频 四川时时彩app下载手机版 开洒店很赚钱吗 浙江11选5 007足球即时比分网 安徽11选5直播 全天北京pk10大小计划 gpk钱龙捕鱼怎么调自动射击 广西快乐双彩